Results 71 to 80 of about 81,803 (228)
Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. [PDF]
PLoS ONE, 2013 BCR-ABL kinase domain inhibition can be used to treat chronic myeloid leukemia. The inhibitors such as imatinib, dasatinib and nilotinib are effective drugs but are resistant to some BCR-ABL mutations.
Karunakar Tanneeru, Lalitha Guruprasad
doaj +1 more source
Cross‐Platform Comparison of Chemoproteomics Workflows: Orbitrap‐TMT Versus timsTOF‐diaPASEF
PROTEOMICS, EarlyView.ABSTRACT Chemoproteomics aims to achieve precise and comprehensive quantification of protein–small molecule interactions, yet methodological comparisons across quantitative proteomics workflows remain scarce. Here, we systematically benchmark tandem mass tag data‐dependent acquisition (TMT‐DDA) on Orbitrap Exploris/Eclipse instruments against label ...
Ursula M. Glocker +7 more
wiley +1 more source
PharmaceuticsBcr-Abl is an oncoprotein with aberrant tyrosine kinase activity involved in the progression of chronic myeloid leukemia (CML) and has been targeted by inhibitors such as imatinib and nilotinib.
Thalia Delgado +12 more
doaj +1 more source
The regulation of bcr-abl in hypoxia is through the mTOR pathway
, 2020 Chronic myeloid leukemia (CML) is usually characterized by the formation of the fusion onco-protein bcr-abl. Therefore, the majority of CML treatments are bcr-abl specific tyrosine kinase inhibitors (TKIs).
Di Trapani, Giovanna +2 more
core +1 more source
Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach [PDF]
, 2010 Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core +1 more source
British Journal of Pharmacology, EarlyView.Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley +1 more source
Post‐Hoc Long‐Read Sequencing Links Leukemic Mutation Status to Single‐Cell Transcriptomes
European Journal of Haematology, EarlyView.ABSTRACT Single‐cell RNA‐sequencing‐based characterization of cells that belong to the neoplastic clone is a major challenge in hematologic neoplasms, where malignant and normal cells coexist. Confident molecular profiling requires simultaneous analysis of gene expression and genetic mutations in individual cells, an ability that is not supported by ...
Sofia Papavasileiou +8 more
wiley +1 more source
Neue Ansätze des molekularen Targetings bei der Philadelphia-Chromosom-positiven Leukämie [PDF]
, 2011 In Philadelphia Chromosome (Ph) positive ALL and CML the fusion between BCR and ABL leads to the BCR/ABL fusion proteins, which induces the leukemic phenotype because of the constitutive activation of multiple signaling pathways down-stream to the ...
Mian, Afsar Ali
core
Delayed Gastric Bleeding in a Patient With Chronic Myeloid Leukemia: A Case of Post‐Biopsy Bleeding
DEN Open, Volume 7, Issue 1, April 2027.The presence of underlying conditions, particularly malignancies such as myeloproliferative disorders, may increase the risk of delayed bleeding following gastric mucosal biopsy, and similar cases warrant careful accumulation and evaluation in future. ABSTRACT A 76‐year‐old man was referred to our hospital for evaluation of anemia.
Yoko Kosaka +3 more
wiley +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Riaz ul-Haq +19 more
core